Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.

Clinical Connection
Thought leadership on the clinical impact on workers' compensation and auto no-fault.
Recent blog posts
![]() |
December 06, 2023 · Clinical Team
FDA warns that the antiseizure medications levetiracetam and clobazam may cause life-threatening adverse reaction. Read more... |
![]() |
November 29, 2023 · Clinical Team
In January, Optum clinical programs will adopt revised morphine equivalent dose (MED) conversion factors for the opioid analgesics hydromorphone, methadone, and tramadol to correlate with CDC Guidelines. However, these modifications are predicted to have little effect on Optum risk identification and clinical review programs. Read more... |
![]() |
November 17, 2023 · Clinical Team
Opvee® (nalmefene) nasal spray now available for emergency treatment of opioid overdoses, but currently non-formulary on all standard formularies until review by Optum P&T Committee. One unit of Opvee will likely be allotted per year by CMS. For WCMSAs, exposure for opioid antagonists like Opvee is unlikely to be significant. Read more... |
![]() |
October 12, 2023 · Clinical Team
The 3Q 2023 Brand-Generic Pipeline update Read more... |
![]() |
September 20, 2023 · Clinical Team
Zavzpret – indicated for the acute treatment of migraine with or without aura in adults – is now available as a 10 mg nasal spray device. Read more... |
![]() |
September 15, 2023 · Clinical Team
According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more... |
![]() |
September 01, 2023 · Clinical Team
Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more... |
![]() |
August 11, 2023 · Clinical Team
FDA approves additional over-the-counter naloxone products Read more... |
Page 1 of 8
Additional Resources
Case Studies
Comorbidity series
Zantac/ranitidine recall updates
Continuing Education
Thought Leadership